Diagnostic role of Helicobacter pylori detection in patients with peptic ulcer

doi:10.3969/j.issn.1673-8640.2021.01.017

Abstract

Abstract:

Objective To investigate the diagnostic role of Helicobacter pylori（Hp） detection in patients with peptic ulcer（PU）. Methods A total of 214 patients with PU（PU group）,146 patients with chronic superficial gastritis（CSG group）,and 118 healthy subjects（control group）were enrolled in this study. All the subjects received ¹⁴C urease breath test,and Hp antibody typing of the 3 groups were detected by immunoblotting. Results The positive rateof ¹⁴C urease breath test of PU,CSG and control groups was 85.51%（183/214）,76.03%（111/146） and 42.37%（50/118）,respectively,and there were significant differences between groups（P<0.05）. The Hp typeⅠinfectious rate of PU and CSG groups was higher than that of control group,and the Hp typeⅠinfectious rate of PU group was higher than that of CSG group（P<0.05）. The cytotoxin-associated protein（CagA）+ vacuolar protein toxin A（VacA） antibody positive rate of PU group and CSG group was higher than that of control group,and CagA+VacAantibody positive rateof PU group was higher than that of CSG group（P<0.05）. CagA+VacA antibody positive ratewas higher than single CagA or VacA antibody positive ratein both PU group and CSG group. Conclusion Hp antibody serotyping assay can provide a reliable reference for clinical diagnosis of PU and hasimportant clinical value.

Key words: Helicobacter pylori, Peptic ulcer, Antibody, Diagnosis

CLC Number:

R573.1

HUANG Ping, WANG Jian, XU Weiqi. Diagnostic role of Helicobacter pylori detection in patients with peptic ulcer[J]. Laboratory Medicine, 2021, 36(1): 84-86.

Figures/Tables 2

References 11

[1]	邹蕊霞,褚传莲,张琳璐,等. 抗体分型检测对幽门螺杆菌感染的诊断价值[J]. 中国现代医学杂志,2019,29(14):65-68.
[2]	NEJATI S,KARKHAH A,DARVISH H,et al.Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders[J]. Microb Pathog,2018,117:43-48.
[3]	袁耀宗,王贞贞. 消化性溃疡诊断与治疗规范(2016年,西安)[J]. 中华消化杂志,2016,36(8):508-513.
[4]	施正超,余铭,李克诚,等. 2009-2014年浙江省瑞安地区幽门螺杆菌常用抗生素耐药监测分析[J]. 中华消化内镜杂志,2015,32( 4 ):257-259.
[5]	KHATOON J,PRASAD K N,PRAKASH R R,et al.Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer[J]. Br J Biomed Sci,2017,74(3):121-126.
[6]	孙新超,秦旭,张德洋,等. 老年患者胃黏膜不同病理形态幽门螺杆菌感染相关性研究[J]. 中华医院感染学杂志,2016,26(17):3881-3882.
[7]	MA J,WU D,HU X,et al.Associations between cytokine gene polymorphisms and susceptibility to Helicobacter pylori infection and Helicobacter pylori related gastric cancer,peptic ulcer disease:a meta-analysis[J]. PLoS One,2017,12(4):e0176463.
[8]	王云龙,陈芬,徐艳琴,等. 细胞毒素相关蛋白A阳性幽门螺杆菌感染与胃癌的相关性及对生长抑素、核因子κB和环氧合酶2的影响[J]. 中华医院感染学杂志,2017,27(3):501-504.
[9]	LI Q,LIU J,GONG Y,et al.Serum VacA antibody is associated with risks of peptic ulcer and gastric cancer:a meta-analysis[J]. Microb Pathog,2016,99:220-228.
[10]	SVERDÉN E,BRUSSELAERS N,WAHLIN K,et al. Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer,ulcer adverse events,and gastric cancer：a population-based cohort study[J]. Gastrointest Endosc,2018,88(2):242-250.e1.
[11]	李毅,李修岭,丁松泽,等. 幽门螺杆菌分型与胃功能检测对胃溃疡的诊断价值[J]. 中华实用诊断与治疗杂志,2019,33(2):156-158.

组别	例数	Ⅰ型Hp	Ⅱ型Hp
PU组	183	145（79.23）^*#	38（20.77）^*#
CSG组	111	75（67.57）^*	36（32.43）^*
对照组	50	19（38.00）	31（62.00）

组别	例数	Ⅰ型Hp	Ⅱ型Hp
PU组	183	145（79.23）^*#	38（20.77）^*#
CSG组	111	75（67.57）^*	36（32.43）^*
对照组	50	19（38.00）	31（62.00）

组别	例数	CagA+VacA 抗体	CagA 抗体	VacA 抗体
PU组	145	118（81.38）^*	17（11.72）^#	10（6.90）^#
CSG组	75	52（69.33）^*	8（10.67）^#	15（20.00）^#
对照组	19	8（42.11）	6（31.58）	5（26.31）

组别	例数	CagA+VacA 抗体	CagA 抗体	VacA 抗体
PU组	145	118（81.38）^*	17（11.72）^#	10（6.90）^#
CSG组	75	52（69.33）^*	8（10.67）^#	15（20.00）^#
对照组	19	8（42.11）	6（31.58）	5（26.31）

[1]	WANG Huiying, TANG Yu, DONG Lili, WANG Jing. Role of Mycoplasma pneumoniae RNA determination in diagnosis and efficacy monitoring of pneumonia in children [J]. Laboratory Medicine, 2023, 38(9): 865-869.
[2]	SUN Xinlin, YE Xingming, LI Qian, ZHAO Lijun. Bronchoscopy combined with sputum Mycobacterium tuberculosis ribonucleic acid and serum Mycobacterium tuberculosis specific antibody determinations for diagnosis of negative pulmonary tuberculosis [J]. Laboratory Medicine, 2023, 38(9): 870-873.
[3]	DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674.
[4]	HAN Xue, WEN Liu, WAN Yang. Analysis of amniotic fluid chromosome karyotype and genome copy number variation in critical or high-risk pregnant women by Down's screening [J]. Laboratory Medicine, 2023, 38(6): 548-552.
[5]	ZHANG Chu, WANG Jianhong, LI Rui, XIAO Yanhua, WANG Heng, ZHANG Pinxiao, XU Ningxin, XIA Banban. Results of non-invasive prenatal testing-plus in 5 696 pregnant women [J]. Laboratory Medicine, 2023, 38(6): 553-558.
[6]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[7]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319.
[8]	XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356.
[9]	HE Xin, LI Yanping. Influence of disease types and clinical indexes on the CMIA determination results of anti-HCV antibody [J]. Laboratory Medicine, 2023, 38(3): 287-290.
[10]	YU Tingting, WANG Jian. Progress and challenges in diagnosis and treatment of rare diseases [J]. Laboratory Medicine, 2023, 38(2): 103-105.
[11]	CAI Xiaoyi, LOU Dan, YANG Xingge, WANG Jian. Genetic analysis on 15 cases of suspected Duchenne muscular dystrophy/Becker muscular dystrophy [J]. Laboratory Medicine, 2023, 38(2): 106-111.
[12]	WANG Dongjiang, GUO Jian. Advance in laboratory diagnosis of invasive fungal infection [J]. Laboratory Medicine, 2023, 38(2): 179-185.
[13]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[14]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[15]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.